ReviewPathologica2022
What's new in the WHO 2022 classification of kidney tumours?
Review in Pathologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 53 citations in OpenAlex.
- Automated Renal Tumor Segmentation in Computed Tomography Images Using a Global Attention-Based DeepLabV3+ Model: Algorithm Development and Validation.JMIR medical informatics · 2026Article
- Renal cell carcinoma: molecular understanding and therapeutic development.Cell death and differentiation · 2026Review
- Renal cell carcinoma with fibromyomatous stroma and renal hemangioblastoma represent a continuum of one tumor spectrum: a comprehensive, critical review of the literature.Virchows Archiv : an international journal of pathology · 2026Review
- From fusion partner to clinical practice: A treatment-oriented framework for transcription factor E3 (Cancer pathogenesis and therapy · 2026Review
- Review
- Eosinophilic renal cell carcinoma colliding with renal perivascular epithelioid cell tumor: a case report.International journal of surgery case reports · 2026Article
- Article
- Review
- Discriminating papillary renal cell carcinoma from metanephric adenoma: a quantitative contrast-enhanced CT-based analysis.Abdominal radiology (New York) · 2026Article
- Cabozantinib in Metastatic Chromophobe Renal Cell Carcinoma: A Single-Center Case Series.Cureus · 2026Article
- Letter to the Editor: Current use of percutaneous ablation in renal tumors-an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy.European radiology · 2026Article
- Rethinking Advanced Renal Cell Carcinoma: Integrative Genomics, Immunotherapy, and Molecular-Orthomolecular Strategies.Cancers · 2026Review
- Recent developments in eosinophilic renal neoplasms: what's new, true and important?Histopathology · 2026Review
- Promoter Hypermethylation-Driven NPHS2 Silencing Promotes Immune Escape and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.Oncology research · 2026Article
- Molecular Drivers of Chromophobe Renal Cell Carcinoma Revealed Through Genomic Analysis Using AACR Project GENIE.Life (Basel, Switzerland) · 2025Article
- The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities.Current oncology (Toronto, Ont.) · 2025Review
- Machine learning studies for predicting 5-year renal cell cancer survival: a multicenter study.Translational andrology and urology · 2025Article
- Molecular and therapeutic landscape of non-clear cell renal carcinoma.Nature reviews. Urology · 2025Review
- Article
- Advances in renal cancer: diagnosis, treatment, and emerging technologies.La Radiologia medica · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) 2022 classification of urinary and male genital tumours (5th edition) has significantly improved our understanding of the morphologic, immunohistochemical, and molecular characteristics of renal tumours. The aim of this review is to outline the most important changes and diagnostic updates in the WHO 2022 classification of kidney tumours. A major change in this edition is the grouping of renal tumours into broader categories that include "
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.